Event:	Central Nervous System Disease Conference
Date/Time:	Thursday, November 17, 2016
Location:	Maxim Group LLC, New York, NY

Related Posts

Anavex Life Sciences Announces Positive Results from Proof of Concept controlled Phase 2 Clinical Trial Evaluating ANAVEX®2-73 (blarcamesine) in Parkinson’s Disease Dementia
October 15, 2020

Anavex Life Sciences Announces Completion of ANAVEX®2-73 (blarcamesine) U.S. Phase 2 Rett Syndrome Clinical Trial
September 10, 2020

Anavex Life Sciences to Present at Upcoming Global Healthcare Conferences Cantor Fitzgerald Global Healthcare Conference 2020 and H.C. Wainwright 22nd Annual Global Investment Conference
September 8, 2020

Anavex Life Sciences Announces Commitment for Financial Investment by Shake It Up Foundation for Parkinson’s Research for Clinical Trial of ANAVEX®2-73 (Blarcamesine) in Patients with Parkinson’s Disease
August 19, 2020